Marella Thorell - 01 Sep 2022 Form 4 Insider Report for Evelo Biosciences, Inc.

Role
Chief Financial Officer
Signature
/s/ Daniel S. Char, Attorney-in-Fact for Marella Thorell
Issuer symbol
EVLO on OTC
Transactions as of
01 Sep 2022
Net transactions value
$0
Form type
4
Filing time
01 Sep 2022, 16:52:50 UTC
Previous filing
18 Jul 2022
Next filing
15 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Stock Option (Right to Buy) Award $0 +440,000 $0.000000 440,000 01 Sep 2022 Common Stock 440,000 $2.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the underlying shares will vest on the first anniversary of the reporting person's employment commencement date (i.e., September 1, 2023), and the remaining 75% of the underlying shares will vest in 36 substantially equal monthly installments thereafter